were included. Analysis showed a small reduction [À6.47 (À8.78, À4.17), P<0.00001] in postoperative pain intensity reported by patients treated with parecoxib compared to controls. Small reductions in the use of rescue analgesia in both the immediate postoperative period and 24 h following surgery were also seen in patients treated with parecoxib. No studies reported any serious adverse events related to parecoxib administration.
Patients with chronic pain commonly complain about poor sleep and likewise people with poor sleep report worse pain. In NHS Grampian Patients attending chronic pain clinics are routinely assessed using the Brief Pain Inventory (BPI). This is a short questionnaire capturing the severity of patients' pain and the extent to which pain interferes with daily functioning, including one question about interference of pain with sleep. There are several dedicated validated tools available for the subjective assessment of sleep. In this pilot study we asked patients with chronic pain to complete the Pittsburgh Sleep Quality Index (PSQI), the Pain and Sleep 3-Item Questionnaire (PSQ-3) and the Verran-Snyder Halpern (VSH) sleep scale in addition to the BPI, to assess whether the sleep interference score in the BPI was able to accurately capture sleep quality.
Following ethical approval and written informed consent, unselected participants were recruited from pain clinics following provision of information about the study a week before the clinic visit. Fifty-one patients (aged 18e88 years) were recruited. BPI pain scores (patients' assessment of their average pain) were subsequently divided into tertiles of mild (scoring 0e4), moderate (5e6) or severe pain (7e10).
Thirteen participants scored their average pain as mild, 16 as moderate and 22 as severe. BPI sleep interference scores correlated significantly with pain scores (r¼0.78, p<0.0001). Sleep disturbance and poor sleep efficiency/quality were identified by the dedicated sleep assessment tools, with significant associations with pain severity tertile. Using the VSH scale which describes sleep over the previous 24h, we found greater sleep disturbance (p¼0.014) and poorer sleep efficiency (p¼0.012) as pain severity increased (Fig. 2) . Likewise using the PSQ-3 which records sleep interference over the last week, sleep disturbance was greater (p<0.0001) and using the PSQI, which assesses sleep over the previous month, the index of poor sleep quality was higher (p<0.0001) as pain increased.
We conclude that more severe pain is associated with worse subjective sleep quality and that the BPI may be useful for rapid initial assessment of sleep in patients with chronic pain.
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We thank the NIAA for a John Snow Intercalated Bursary award to Rachel Vaughan. There is currently no consensus as to which tools should be used to measure and record post operative pain, with variation in clinical, audit and research practice 2 . To assess whether a national consensus of core outcome measures in post-operative pain is necessary or desired, a survey of current UK practice and opinion was undertaken. A paper-based survey was distributed to all attendees at the National Acute Pain Symposium (NAPS), held in September 2017. Questionnaires were completed by 114 (63%) delegates, including 57 Acute/Chronic pain nurses, 44 Consultants or Associate Specialists in Anaesthesia and/or Pain Medicine, 9 Specialty Trainees in Anaesthesia, 3 Allied Health Professionals and 1 Orthopaedic Surgeon. 57% delivered services at tertiary referral hospitals. Almost all respondents cared for adult patients, with 36% having a paediatric caseload, and 20% responding to obstetric referrals.
Outcome data were collected routinely by 60% of respondents. Forty-four percent used an excel spreadsheet for analysis, 16% used specialist medical databases, and others reported using paper-based departmental records or the Electronic Patient Record (EPR).
All respondents reported using more than one post-operative pain assessment tool, with 17 different scoring tools currently used across the UK. The most commonly used were the Verbal Rating Scale (75%), Visual Analogue Scale (54%), Numerical Rating Scale (60%), FACES (50%) and the Abbey Pain Scale, for patients who are unable to verbalise (39%).
Most centres recorded pain on both movement and rest (83%), though a number of individuals reported that their new EPR systems would not allow this. Psychological components of pain experience were rarely assessed (10%), mostly in response to referral for complex pain issues rather than as part of routine practice.
Whilst only 31% of respondents were aware of local trust guidelines for post-operative pain assessment, 71% were aware of national guidelines. Four percent of respondents disagreed that a national consensus on post-operative pain outcome measurements would be of value to their clinical practice and for use in local quality improvement initiatives.
The results of this national survey reveal variation in practice in the methods of measuring and recording postoperative pain outcomes and a desire to determine a national consensus of which core outcome measures should be used to guide best practice and allow for a more rigorous approach to improvement science in acute pain. Individual units could use this set of core outcome measures, to submit to a national database to enable benchmarking, and to drive co-ordinated quality improvement.
Postoperative pain after total knee replacement. Which non-steroidal antiinflammatory drugs should be used? Postoperative pain after total knee arthroplasty is a major concern for both patients undergoing the procedure and doctors, as it is difficult to control and can be quite extreme. Currently, a mixture of NSAIDs and opioids is commonly used in order to alleviate the pain, however it is still not known which NSAIDs are the most effective in terms of pain management and side-effect control. Accordingly, there are no respective guidelines. The aim and objective of this structured review was to search, identify, review and critically appraise the existing articles, relevant to the topic. The study was designed as a systematic review, focusing on the selection/usage of NSAIDs in postoperative pain management in patients after total knee replacement.
The online databases (PubMed 1 and Scopus 2 ) were searched and articles that met the inclusion criteria e i.e. Randomised controlled trials; articles published after 01/12/ 1999; specific procedure e total knee arthroplasty; specific type of pain e postoperative pain; NSAIDs usage as the main type of adjunctive analgesics were identified. The main exclusion criteria were: Additional different analgesic techniques; nonhuman species; full text not available online.
We critically appraised the articles using PRISMA statement 3 and CASP checklists 4 , and summarised and compared the obtained results. Overall, five articles meeting the set criteria were identified to be relevant to this review. In particular, we looked at the levels of pain and incidence of opioid-related side-effects as outcome measures for each paper reviewed.
The review established that five different NSAIDs in combination with opioids had been used (Lornoxicam, Parecoxib sodium, Etoricoxib, Tenoxicam, and Celecoxib). All these drugs contributed to varying degrees to postoperative analgesia, however only Lornoxicam showed a significant opioid-sparing effect, thereby decreasing the incidence of opioid related side-effects. 5 This systematic review shows that so far there is very limited Level 1b evidence 6 to support a rational choice of NSAIDs as adjuncts to postoperative analgesia after total knee arthroplasty. Consequently, further clinical research is necessary. A particular focus on the effects of Lornoxicam in this context may have merit.
Ratifying the dosage and duration of levobupivacaine infusion by the caudal-epidural route in infants aged three to six months The pharmacokinetics of levo-bupivocaine are age-dependent. 1 Current paediatric protocols for caudal-epidural infusions of levo-bupivacaine are derived from bupivacaine-based pharmacokinetic modelling aiming for plasma levels below 2-2.5 mg/ ml 2 . Levo-bupivacaine levels have been evaluated following single caudal-epidural boluses 3 . However, no studies have investigated this in infants less than 6 months with a single bolus followed by an infusion. This phase-II/III clinical trial aims to validate levo-bupivacaine pharmacokinetic modelling in infants aged 3-6months and ensure that toxic levels are not being reached by present protocols of levo-bupivacaine (i.e.
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